REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
Status:
Recruiting
Trial end date:
2026-08-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in
combination with standard first-line platinum-based chemotherapy compared to chemotherapy
alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.